Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

NS Investment

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 19
Average round size
info
The average size of a deal this fund participated in
$98M
Portfolio companies 17
Rounds per year 3.17
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 6
Key employees 2

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Pharmaceutical
Summary

NS Investment is the famous VC, which was founded in 2016. The fund was located in Asia if to be more exact in South Korea. The main department of described VC is located in the Seoul.

The typical case for the fund is to invest in rounds with 9-10 participants. Despite the NS Investment, startups are often financed by The Column Group, Topspin Partners, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are The Column Group, Sofinnova Investments, OrbiMed. In the next rounds fund is usually obtained by Topspin Partners, The Column Group, Taiho Ventures.

We can highlight the next thriving fund investment areas, such as Biotechnology, Emergency Medicine. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Antiva Biosciences, Surrozen, Fulcrum Therapeutics. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 2 or 4 of the founder, the chance for it to get the investment is meager.

The top amount of exits for fund were in 2019. The important activity for fund was in 2018. Comparing to the other companies, this NS Investment performs on 14 percentage points more the average number of lead investments. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund.

We also calculated 2 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of NS Investment:
Typical Co-investors
NS Investment is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after NS Investment:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Cystic Fibrosis Trust England, London, United Kingdom
Dembach Goo Informatik GmbH & Co. KG Cologne, Germany, Nordrhein-Westfalen
Guangzhou Yi Capital Investment Management -
Henkel Ventures Düsseldorf, Germany, Nordrhein-Westfalen
Honghui Capital -
Lonsdale Capital Partners England, London, United Kingdom
MAG Ventures Connecticut, Norwalk, United States
Next Coast Ventures Austin, Texas, United States
Tietoa Finland Oy -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Aktis Oncology

Biotechnology
Life Science
$84M25 Aug 2022 Boston, Massachusetts, United States

Aspen Neuroscience

Biotechnology
Medical
Pharmaceutical
Therapeutics
$147M09 May 2022 San Diego, California, United States

Dewpoint Therapeutics

Biotechnology
Medical
Therapeutics
$150M03 Feb 2022 Cambridge, Massachusetts, United States

Maze Therapeutics

Biotechnology
Therapeutics
$190M10 Jan 2022 Redwood City, California, United States

Shoreline Biosciences

Biotechnology
Life Science
Medical
$140M02 Nov 2021 San Diego, California, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$80M21 Oct 2021 Dallas, Texas, United States

Immunitas Therapeutics

Biotechnology
Life Science
Therapeutics
$58M18 Aug 2021 Cambridge, Massachusetts, United States

Sonoma BioTherapeutics

Biotechnology
Life Science
Therapeutics
$265M04 Aug 2021 South San Francisco, California, United States

Accent Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$63M23 Apr 2020 Lexington, Kentucky, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent NS Investment?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: